# High Dose BAYA1040 CR: a Long Term Extension Study

Study · id `cardio:ct-nct01355367` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01355367](<https://clinicaltrials.gov/study/NCT01355367>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01355367

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 120 participants.

## Technical summary

Registry record NCT01355367. Non-randomized; no masking; primary purpose treatment. Start 2011-01 (registry gives no type); primary completion 2011-09 (actual). Results not posted.

## Key facts

- Design: Interventional study; non-randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 120 participants (enrolled count; ClinicalTrials.gov record NCT01355367, source copy `cardio:ctgov-nct01355367-2014-01-29`, retrieved 2026-10-26)
- Start date: 2011-01 (registry gives no type) (ClinicalTrials.gov record NCT01355367, source copy `cardio:ctgov-nct01355367-2014-01-29`, retrieved 2026-10-26)
- Primary completion: 2011-09 (actual) (ClinicalTrials.gov record NCT01355367, source copy `cardio:ctgov-nct01355367-2014-01-29`, retrieved 2026-10-26)
- Completion: 2012-04 (actual) (ClinicalTrials.gov record NCT01355367, source copy `cardio:ctgov-nct01355367-2014-01-29`, retrieved 2026-10-26)
- Countries: Japan (ClinicalTrials.gov record NCT01355367, source copy `cardio:ctgov-nct01355367-2014-01-29`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01355367-2014-01-29`, retrieved 2026-10-26)

## The registry's words

- Brief title: High Dose BAYA1040 CR: a Long Term Extension Study
- Condition: Hypertension
- Intervention (Drug): Nifedipine (Adalat, BAYA1040)
- Lead sponsor: Bayer
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Nifedipine (`cardio:nifedipine`)
- Registry intervention is a member of this class by a sourced record link: Calcium channel blockers (`cardio:calcium-channel-blockers`)
- Registry lists this organization as the lead sponsor: Bayer (`cardio:bayer`)

## Provenance

Content hash: 8ceffb70dd414e08396ef217563050012c2172e06256f62b5ec835b133931436
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
